ACHV Achieve Life Sciences, Inc.
Financings ·
Achieve Life Sciences agreed on April 15, 2026 to sell shares, pre-funded warrants and warrants for anticipated gross proceeds of about $180.0 million, with up to $173.8 million more if the warrants are exercised. Chief Executive Richard Stewart steps down on April 18, 2026.
Achieve priced 15,000,000 shares, each sold with a five-year warrant at $3.00, for $45,000,000 in gross proceeds, below the $3.51 last reported sale price on June 26, 2025. The company's 2024 annual report carried a going-concern warning.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $22.8 million | |
| Net income (loss) | -$54.6 million | -$39.8 million |
| Cash from operations | -$49.5 million | -$29.8 million |
| Cash and equivalents | $20.9 million | $12.8 million |
| Short-term investments | $15.5 million | $21.6 million |
Our latest story on this, dated Jun 26, 2025: "Achieve Life Sciences prices $45,000,000 offering of stock and warrants at $3.00". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 16, 2026: "Achieve Life Sciences agrees to $180 million private placement; CEO Richard Stewart to step down". The story links the filing or release it is based on. Read the story.
Achieve Life Sciences, Inc. trades under the ticker ACHV on NASDAQ.
Achieve Life Sciences, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:SP4P.
The SEC Central Index Key (CIK) for Achieve Life Sciences, Inc. is 949858. Its filings are on SEC EDGAR.
102,902,490 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Achieve Life Sciences, Inc. under United States.
Our directory classifies Achieve Life Sciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Achieve Life Sciences, Inc. is US0044685008.
aibio.space lists Achieve Life Sciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Achieve Life Sciences, Inc. reported a net loss of $54.6 million for the fiscal year ended Dec 31, 2025, and used $49.5 million of cash in operations, per its annual report to the SEC.
$187.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Achieve Life Sciences, dated Apr 16, 2026: "Achieve Life Sciences agrees to $180 million private placement; CEO Richard Stewart to step down". Achieve Life Sciences agreed on April 15, 2026 to sell shares, pre-funded warrants and warrants for anticipated gross proceeds of about $180.0 million, with up to $173.8 million more if the warrants are exercised. Chief Executive Richard Stewart steps down on April 18, 2026. Source.
From our story of Jun 26, 2025: The company's 2024 annual report carried a going-concern warning. Source.
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio